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Paget’s disease of bone (PDB) is a common disorder characterised by focal 
abnormalities of bone remodelling. We previously identified variants at the CSF1, 
OPTN and TNFRSF11A loci as risk factors for PDB by genome wide association study1. 
Here, we extended this study, identified three new loci and confirmed their association 
with PDB in 2,215 cases and 4,370 controls from seven independent populations. The 
new associations were with rs5742915 within PML on 15q24 (OR=1.34; P= 1.6 x 10-14); 
rs10498635 within RIN3 on 14q32 (OR= 1.44; P= 2.55 x 10-11) and rs4294134 within 
NUP205 on 7q33 (OR=1.45; P= 8.45 x 10-10). Our data also confirmed the association of 
TM7SF4 (rs2458413; OR=1.40; P= 7.38 x 10-17) with PDB. The seven loci explained a 
substantial proportion of familial risk of PDB (~13%). These studies provide new 
insights into the genetic architecture and pathophysiology of PDB.  
Paget’s disease of bone (PDB) is a common skeletal disorder with a strong genetic 
component that affects up to 2% of individuals of European ancestry aged 55 years and 
above2,3. Mutations of the SQSTM1 gene are known to cause a high penetrance form of PDB 
which is clinically severe4 and occurs in about 40% of patients with a family history of the 
disorder5,6. We recently identified additional susceptibility alleles for PDB at the CSF1, 
OPTN, and TNFRSF11A loci by a genome wide association study (GWAS) involving 692 
PDB cases and 1,001 controls with replication cohort of 481 cases and 520 controls1. In order 
to identify additional susceptibility loci for the disease, we  performed an extended GWAS 
involving a total of 749 PDB cases of British descent in whom SQSTM1 mutations had been 
excluded and 2,930 British controls derived from the 1958 Birth Cohort7 with replication in a 
further 1,474 cases and 1,671 controls from six independent populations. 
After applying quality control measures and excluding samples of non-European 
ancestry, the extended cohort (henceforth referred to as the GWAS stage) comprised 741 
cases and 2,699 controls with genotype information for 290,115 SNPs, providing a 4-fold 
increase in power to detect loci of moderate effect size (odds ratio ≥ 1.4) compared with our 
previous study1. To increase SNP coverage, we performed genome wide SNP imputation for 
the GWAS stage samples using phased haplotype data from the HapMap project as a 
reference. The results of association testing of genotyped and imputed SNPs (total 2,487,078 
SNPs) from the GWAS stage are shown in Fig. 1. A locus on chromosomes 8q22.3 showed 
genome-wide evidence of association with PDB (P < 5.0 x 10-8) in addition to the previously 
identified genome wide significant loci on 1p13.3, 10p13 and 18q21.331.  
In the second stage of this study we analysed the highest ranking SNPs observed in the 
GWAS stage (P values of 5 x 10-5 or less) for replication after excluding those in linkage 
disequilibrium (LD; r2 > 0.8 or D’ > 0.95) with the highest ranking SNP from each region. A 
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total of 27 SNPs were genotyped in the replication cohorts which consisted of 1,474 
SQSTM1-negative PDB cases from six different geographic regions and 1,671 unaffected 
controls from the same regions that were matched with the cases by gender as described in the 
online methods section and Supplementary Table 1. A meta-analysis of data from the 
GWAS stage and individual replication cohorts was performed and the results are summarised 
in Supplementary Table 2. This strengthened the association with PDB for the CSF1, OPTN, 
and TNFRSF11A loci which were identified in our previous study1 and confirmed the 
association with 8q22.3 locus which was suggestively associated with PDB in our previous 
GWAS1 and was confirmed to be associated with PDB in a small study of Belgian and Dutch 
subjects8. Furthermore, three additional genome wide significant loci on 7q33, 14q32.12, and 
15q24.1 were identified in the combined data set (P < 5 x 10-8; Table 1 and Fig. 2).  
The strongest signal on 8q22.3 was with rs2458413 (combined P-value = 7.38 x 10-17; 
OR = 1.4). There was no significant heterogeneity between the study groups (Table 1, Fig. 3 
and Supplementary Table 3) and the direction of association was similar in all cohorts. The 
associated region spans ~220kb but SNPs with the highest association signal appear to cluster 
within an 18-kb LD block spanning the entire Transmembrane 7 superfamily member 4 gene 
(TM7SF4; Fig. 2 and Supplementary Fig. 1). This gene encodes dendritic cell-specific 
transmembrane protein (DC-STAMP)9 which is a strong functional candidate gene for PDB 
since it is required for the fusion of osteoclast precursors to form mature osteoclasts10. 
Previous studies have shown that RANKL induced DC-STAMP expression is essential for 
osteoclast formation11 and a recent study showed that the connective tissue growth factor 
CCN2 stimulates osteoclast fusion through interaction with DC-STAMP12.  Since osteoclasts 
from patients with PDB are larger in size and contain more nuclei than normal osteoclasts, it 
seems likely that the genetic variants that predispose to PDB do so by enhancing TM7SF4 
expression or by causing gain-of-function at the protein level but further studies will be 
required to investigate these possibilities.  
The first new locus for PDB susceptibility was on 7q33 tagged by rs4294134 (combined 
P-value = 8.45 x 10-10; OR = 1.45).  The direction of association was similar in all study 
cohorts and analysis of the combined data set showed no evidence for heterogeneity between 
study groups (Table 1, Fig. 3 and Supplementary Table 3). The associated region spans 
~350kb (Fig. 2) but the strongest signal was with rs4294134, located within the 22nd intron of 
NUP205. This gene encodes nucleoporin 205kDa which is one of the main components of the 
nuclear pore complex involved in the regulation of transport between the cytoplasm and  
nucleus13. All SNPs with P < 1 x 10-5 in the 350kb associated region were in moderate to 
strong LD with rs4294134 (r2 ≥ 0.5; D’ ≥ 0.95) with the exception of two SNPs (rs3110788 
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and rs3110794) which were poorly correlated with rs4294134 (r2 ≤ 0.21; D’ ≥ 0.95; Fig. 2). 
Conditional analysis in the GWAS stage indicated that the association signal appeared to be 
driven by rs4294134 (P = 8.8 x 10-3) after adjusting for rs3110788 (P = 0.31) and rs3110794 
(P = 0.10). None of the genes located in this region are known to affect bone metabolism and 
further studies will be required to identify the functional variant(s) responsible for association 
with PDB.   
The second new susceptibility locus was located on 14q32.12 and was tagged by 
rs10498635. This SNP showed borderline evidence of association with PDB in our previous 
study (P = 9.69 x 10-8)1 but reached genome-wide significance in the present study (combined 
P-value = 2.55 x 10-11; OR = 1.44).  Association testing showed no evidence for heterogeneity 
between the study groups (Table 1, Fig. 3 and Supplementary Table 3). The 62kb-
associated region is bounded by two recombination hotspots and contains the gene RIN3 (Fig. 
2) that encodes the Ras and Rab interactor 3, a protein that plays a role in vesicular trafficking 
through interaction with small GTPases such as Ras and Rab14,15.  The function of RIN3 in 
bone metabolism is currently unknown, but it could play a role in bone resorption in view of 
the importance that small GTPases play in vesicular trafficking and in osteoclast function16,17. 
It is of interest to note that mutations affecting the VCP, a protein also involved in vesicular 
trafficking, cause the syndrome of inclusion body myopathy with early-onset Paget’s disease 
and frontotemporal dementia (IBMPFD)18. 
The third new susceptibility locus was located on 15q24.1 and the strongest association 
was with rs5742915 (combined P-value = 1.60 x 10-14; OR = 1.34; Table 1, Fig. 3 and 
Supplementary Table 3). The associated region is bounded by two recombination hot spots 
and spans ~200kb but a gap spanning ~40kb was observed in this region with no SNP 
coverage in the illumina arrays or the HapMap CEU population. The associated SNPs were 
clustered within the promyelocytic leukaemia gene (PML; Fig. 2) and the strongest signal was 
observed for rs5742915, which results in a phenylalanine to leucine amino acid change at 
codon 645 (F645L) of the PML protein. The function of PML in bone metabolism is unclear 
but it is known to be involved in TGF-β signalling19. Accordingly Lin et al showed that cells 
from pml knock out mice were resistant to TGF-β-dependent growth arrest and apoptosis and 
had impaired induction of TGF-β target genes19. Since TGF-β is known to play a role in the 
regulation of bone remodelling, it is possible that the association between PDB and PML 
could be mediated by an effect on TGF-β signalling, but further research will be required to 
investigate this possibility. The GOLGA6A gene is also located in the associated region and 
encodes a protein that belongs to golgin, a family of coiled-coil proteins associated with the 
Golgi apparatus and play a role in membrane fusion and as structural supports for the Golgi 
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cisternae.  This gene is located in the 40kb gap region that contains a large low-copy repeat 
sequence. Although the GOLGA6A has no known role in bone metabolism, mutations in other 
members of the golgin family have been shown to cause a lethal skeletal dysplasia20, and a 
severe form of osteoporosis21. 
We were also able to replicate our previously reported association between variants at 
the CSF1, OPTN, and TNFRSF11A loci and PDB in the present study1. The results of meta-
analysis of the combined data set for these loci are shown in Table 1 and Supplementary 
Fig. 2 which provide conclusive evidence for association of variants at CSF1 (P = 7.06 x 10-
35), OPTN (P = 4.37 x 10-38), and TNFRSF11A (P = 7.98 x 10-21) with PDB. Evidence of 
heterogeneity between study groups was observed for rs1561570 (I2 = 65.7%; Phet = 0.01) at 
OPTN but this was due to differences in effect size rather than the direction of effect and the 
association remained genome wide significant after accounting for heterogeneity (P = 4.34 x 
10-12; OR = 1.68). The heterogeneity was caused by larger effect size observed in the Dutch 
cohort (Supplementary Fig. 2) possibly due to the small sample size of this cohort. These 
observations provide highly robust evidence for association between these loci and PDB and 
extend those recently reported8 in the Dutch and Belgian populations which were also 
included in the present study. 
We next wanted to determine if the identified loci on 15q24.1, 7q33 and 14q32.12 
interacted with each other or with the previously identified loci on 1p13.3, 8q22.3, 10p13 and 
18q21.33 to affect the risk of PDB. Pair-wise interaction analysis showed weak evidence for 
interaction between 7q33 (rs4294134) with 8q22.3 (rs2458413; P = 0.03) and 10p13 
(rs1561570; P = 0.02). However, these interactions were not significant after adjusting for 
multiple testing and none of the other loci showed evidence for interaction (P > 0.05) 
suggesting a multiplicative model of association with PDB risk. In order to estimate the effect 
size of the identified loci on the development of PDB, we calculated the proportion of familial 
risk explained by the genome wide significant loci in the replication sample assuming a 
sibling relative risk for PDB of 7.022. This showed that the proportion of familial risk 
explained was ~13% which is much greater than observed for other bone diseases like 
osteoporosis23. We also estimated the cumulative population attributable risk of these loci in 
the replication cohort and found it to be 86% and we found that the risk of PDB increased 
with increasing number of risk allele scores defined by the seven loci (ORper-riskallele = 1.44, 
95% CI = 1.38 – 1.51, P = 5.4 x 10-57). When allele scores were weighted according to their 
estimated effect size we found that subjects in the top 10% of the allele score distribution 
(D10; n = 315) had 10.1 fold (95%CI; 7.0 – 14.6; P = 2.4 x 10-39) increase in risk of 
developing PDB compared to those in the bottom 10% of the distribution (D1; n = 315) from 
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the replication dataset (Fig.4). Although these data suggest that a large part of the genetic risk 
of PDB in patients without SQSTM1 mutations is accounted for by these loci, we 
acknowledge that the functional variants need to be identified before we can precisely 
estimate the contribution that these loci make to the risk of developing PDB. To assess the 
functional effect of the identified SNPs on gene expression, we tested the association between 
top PDB-associated SNPs (or those in LD; D’≥0.8) from each of the seven loci and cis-allelic 
expression of genes located in the associated regions using publicly available expression 
quantitative trait loci (eQTL) data. This showed highly significant associations for transcripts 
of TM7SF4 (rs2458415; expression P-value = 1.22 x 10-18) and OPTN (rs1561570; expression 
P-value = 6.61 x 10-62) in peripheral blood monocytes24 suggesting that the association with 
PDB risk for these loci could be mediated by influencing gene expression levels.  
In addition to the loci mentioned above, additional variants were identified that showed 
suggestive evidence for association with PDB. For example a locus on chromosome Xq24 
showed borderline evidence for association with PDB (rs5910578 within SLC25A43 gene; 
combined P = 1.26 x 10-7; OR = 1.34) as did another locus on chromosome 6p22.3 
(rs1341239 near PRL gene; combined P = 3.83 x 10-6; OR= 1.20; Supplementary Table 2). 
Given that we observed 6 genotyped variants with P < 1 x 10-5 in the GWAS stage after 
removal of confirmed SNPs and associated variants when we only expect 3 by chance 
(Supplementary Fig. 3), it is likely that some of the associations observed are true but our 
study was not sufficiently powered to detect them at a genome wide significance level (P < 5 
x 10-8).  
This study has been successful in identifying seven loci that contribute substantially to 
the risk of developing PDB. The identified loci have relatively large effect sizes compared 
with other common diseases such as osteoporosis and rheumatoid arthritis. This indicates that 
susceptibility to PDB is most probably mediated by inheritance of a relatively small number 
of genes with large effect sizes as opposed to a large number of genes with small effect sizes 
as seen in other complex diseases.  Many of the susceptibility variants lie within or close to 
genes that are known to play important roles in regulating osteoclast differentiation and 
function whereas other variants lie within genes not previously implicated in the regulation of 
bone metabolism. Whilst further work will be required to identify the functional variants, the 
present study has provided new insights into the genetic architecture of PDB and has 
identified several genes that previously were not suspected to play a role in bone metabolism. 
Finally, the large effect size of the variants identified means that it may be possible in the 
future to identify people at risk of developing PDB by genetic profiling.  
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FIGURE LEGENDS 
 
Figure 1. Loci for susceptibility to PDB detected by genome wide association study. 
Manhattan plot of association test results of GWAS stage data showing chromosomal position 
of 2,487,078 genotyped or imputed SNPs plotted against genomic-control adjusted –log10 P. 
The red horizontal line represents the threshold for genome wide significance (P < 5 x 10-8). 
 
Figure 2. Regional association plots of loci showing genome wide significant association 
with PDB. Details of loci on chromosome (a) 7q33, (b) 15q24.1, (c) 8q22.3 and (d) 14q32.12 
showing the chromosomal position (based on NCBI human genome build 36) of SNPs in each 
region plotted against –log10 P values. Genotyped (squares) and imputed (circles) SNPs are 
colour-coded according to the extent of linkage disequilibrium with the SNP showing the 
highest association signal (represented as purple diamonds) from each region in the combined 
analysis The estimated recombination rates (cM/Mb) from HapMap CEU release 22 are 
shown as light blue lines and blue arrows represent known genes in each region. The 
associated regions were defined based on LD with the highest association signal (r2 > 0.2) 
within a window of 500kb.   
 
Figure 3. Forest plots of overall effect size for SNPs associated with PDB risk from the 
identified loci on (a) 7q33 (rs4294134), (b) 8q22.3 (rs2458413), (c) 14q32.12 (rs10498635), 
and (d) 15q24.1 (rs5742915). The overall effect size was estimated using meta-analysis of the 
GWAS sample and the six replication samples. The black squares represent the effect 
estimates for the individual cohorts and the horizontal lines represent the 95% confidence 
interval of the estimates. The sizes of the squares are proportionate to the weight of the 
estimate.  The diamonds and triangles represent the overall estimate under fixed effect and 
random effects model, respectively. The dotted vertical lines represent the overall fixed effect 
estimates. 
 
Figure 4. Cumulative contribution of genome-wide significant loci to the risk of PDB. Risk 
allele scores defined by the seven loci associated with PDB risk is plotted against the odds 
ratio (OR) for PDB. Risk alleles were weighted according to their estimated effect size and 
weighted risk allele scores were divided into ten equal parts (deciles) using data from the 
replication cohorts.  The OR for PDB risk was calculated for each decile in reference to the 
fifth decile (D5).  Vertical bars represent 95% confidence intervals. 
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Table 1. Summary of the seven loci showing genome-wide significant association with Paget’s disease of bone. 
   GWAS Stage Replication Combined Overall Effect  
   Fixed effect Fixed effect Heterogeneity  
Chr SNP RA P OR (95%CI) P OR (95%CI) P OR (95%CI) Phet I2 Closest Gene
1 rs10494112 G 5.83 x 10-17 1.75 (1.54 – 1.99) 4.93 x 10-19 1.69 (1.50 – 1.89) 7.06 x 10-35 1.72 (1.57 – 1.87) 0.97 00.0 
CSF1, 
EPS8LS
7 rs4294134 G 1.20 x 10-05 1.50 (1.25 – 1.79) 2.29 x 10-05 1.42 (1.20 – 1.66) 8.45 x 10-10 1.45 (1.29 – 1.63) 0.83 00.0 NUP205 
8 rs2458413 A 7.85 x 10-11 1.51 (1.34 – 1.71) 1.09 x 10-07 1.32 (1.19 – 1.46) 7.38 x 10-17 1.40 (1.29 – 1.51) 0.10 44.3 TM7SF4 
10 rs1561570a T 9.56 x 10-18 1.71 (1.51 – 1.93) 2.09 x 10-21 1.64 (1.48 – 1.81) 4.37 x 10-38 1.67 (1.54 – 1.80) 0.01 65.7 OPTN 
14 rs10498635 C 1.51 x 10-05 1.45 (1.23 – 1.71) 5.64 x 10-07 1.42 (1.29 – 1.63) 2.55 x 10-11 1.44 (1.29 – 1.60) 0.62 00.0 RIN3 
15 rs5742915 C 1.40 x 10-07 1.38 (1.22 – 1.54) 3.99 x 10-08 1.32 (1.20 – 1.46) 1.60 x 10-14 1.34 (1.25 – 1.45) 0.56 00.0 PML 
18 rs3018362 A 1.87 x 10-11 1.50 (1.34 – 1.69) 1.27 x 10-10 1.40 (1.26 – 1.55) 7.98 x 10-21 1.45 (1.34 – 1.56) 0.46 00.0 TNFRSF11A
RA, risk allele; OR, odds ratio for the risk allele; CI, confidence interval; I2, heterogeneity statistics; Phet, P-value for heterogeneity. Newly 
identified loci are shown in bold letters. ars1561570 showed significant heterogeneity but random-effect results were genome-wide significant (P 
= 4.34 x 10-12; OR = 1.68). 
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ONLINE METHODS 
 
GWAS stage study subjects. This study describes an extension to our previously reported 
GWAS of PDB in which we used genotype data from 692 PDB cases from our previously 
described study1, and extended the case group by genotyping an additional 57 PDB cases. The 
additional cases were selected from recently recruited subjects in the PRISM study25; a 
randomised trial of two different treatment strategies for PDB patients from the UK.  We also 
increased the size of the control group by using genotype data from 2,930 subjects from the 
British 1958 Birth Cohort genotyped by the Wellcome Trust Case-Control Consortium7. This 
control group represents a better match to our PDB cases than the previous controls which 
were recruited from Scotland1 since, like the PRISM participants, they were recruited from all 
over the UK. The extended samples size used in this study provided 90% power to detect 
disease associated allele with MAF = 0.2 and genotype relative risk of 1.4 assuming a 
multiplicative model and a disease with population prevalence of 2%. This represents a 
substantial increase in power compared to our previous study1 where we had 20% power to 
detect alleles with genotyped relative risk of 1.4.  
 
GWAS stage genotyping and quality control. Genotyping and quality control for the 692 
PDB cases were performed using Illumina HumanHap300-Duo arrays as described 
previously1. The additional 57 PDB cases were genotyped using Illumina Human660W Quad 
version 1 arrays and quality control measures were applied as previously described1. Briefly; 
SNPs with call rate < 95% were excluded and samples with call rate < 90% (n=1); excess 
heterozygosity (n=1); and non-European ancestry (n= 6; Supplementary Fig. 4) were 
removed before analysis. The genotyping of the British 1958 Birth Cohort was previously 
performed by the Wellcome Trust Case-Control Consortium using the Illumina Human 1.2M 
Duo custom array (www.wtccc.org.uk.)7. For the control group, SNPs with call rate <95% 
were excluded and we removed 231 samples because they failed at least one of the following 
quality control criteria: low call rate, non-European ancestry, gender mismatch, or cryptic 
relatedness. Population ancestry was determined using multidimensional scaling analysis of 
identity-by-state (IBS) distances matrix as previously described1. After quality control, we 
analysed 741 PDB cases and 2,699 controls with genotype data for 290,115 SNPs which were 
common to the three different genotyping arrays. To ensure consistent genotyping between 
different platforms, a subset of samples were genotyped using at least two different platforms 
and cross-platform genotype concordance rate was > 99.7% (Supplementary Table 4). 
Additionally, the genotype cluster plots for all SNPs showing association with PDB at P < 1.0 
x 10-4 were visually inspected in cases and controls and only high quality genotype data were 
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included in the analysis. Furthermore, genotype call rate for the top associated SNPs was 
consistent between cases and controls (Supplementary Table 5).   
 
Replication samples. The replication study groups were derived from clinic-based PDB 
patients and gender-matched controls selected from the same region. Patients with SQSTM1 
mutations were excluded and all study participants provided informed consent. The first 
replication cohort comprised 175 PDB patients from the UK; 8 PDB cases from Sydney 
Australia and 215 PDB cases from Western Australia. These patients were of British descent 
and were matched with 485 unaffected British controls. The second replication cohort (Italian 
replication cohort 1) comprised 354 PDB cases and 390 unaffected controls enrolled from 
various referral centres in Italy who took part in the GenPage project26. The third replication 
cohort (Italian replication cohort 2) comprised 205 Italian PDB cases and 238 unaffected 
controls enrolled from referral centres in Northern, Central and Southern Italy as previously 
described27. The fourth replication cohort comprised 246 sporadic PDB patients recruited 
from various referrals centres in Belgium and these were matched with 263 controls with no 
clinical evidence of PDB as previously described8. The fifth replication cohort comprised 85 
PDB patients and 93 controls recruited from various centres in the Netherlands as 
described8,28. The sixth replication comprised 186 sporadic PDB cases recruited from the 
Salamanca region in the Castilla-Leon region of Spain and 202 unaffected controls from the 
same region. 
 
Replication sample genotyping and quality control. Genotyping of replication samples was 
performed by Sequenom (Hamburg, Germany) using the MassARRAY iPLEX platform. To 
minimize genotyping bias due to variations between runs; DNA from cases and controls from 
the six different replication cohorts were distributed into 384-well plates so that each plate 
had the same number of cases and controls. We included 4000 known genotypes as a quality 
control measure and the concordance rate between the genotype calls was > 99.8%. We 
removed 64 samples due to low call rate (< 90%) and the call rate for all genotyped SNPs was 
>95%. 
 
Imputation. Genome-wide genotype imputation for autosomal SNPs was performed using 
MACH29 and the HapMap European (CEU) phased haplotype data from release 22 were used 
as a reference. We excluded SNPs with poor imputation quality based on the estimated 
correlation between imputed and true genotypes (r2 < 0.3). Additionally, a subset (2%) of 
known genotypes were masked during imputation and then imputed genotypes were 
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compared with true genotypes and the average per allele imputation error rate was 2.9%. 
Imputed SNPs were tested for association using PorbABEL software30 implementing a 
logistic regression model in which the allelic dosage of imputed SNP was used to adjust for 
uncertainty in imputed genotypes. 
 
Statistical analysis. Statistical analyses were performed using PLINK (Version 1.07) 31 
and R (v2.11.1). In GWAS stage, genotyped SNPs were tested for association with PDB using 
standard allelic (1.d.f) χ2 statistic. We also performed association testing using regression 
models in which we adjusted for gender, population clusters (as determined by 
multidimensional scaling analysis) but results were essentially identical to those obtained 
from the standard allelic test reported here (data not shown).  The genomic inflation factor λGC 
was calculated based on the 90% least significant SNPs as described previously32. The 
observed test statistic values were corrected using the genomic control method (λGC = 1.05; 
Supplementary Fig. 3). Logistic regression was used to test for independent effects of SNPs 
where the allelic dosage of the conditioning SNP was entered as a covariate in the regression 
model. To assess if the reported associations were confounded by age, age of onset or 
recruitment centre, we performed a regression analysis using case-only data from the GWAS 
stage to test if any of these factors were associated with the top hits using linear regression 
models. The results of this analysis showed no evidence to suggest that the reported 
association is confounded by age, age of onset, or recruitment centre (P > 0.10). The cut off 
point for genome wide significance was set as P < 5 x 10-8 as recently proposed33. Association 
testing of replication data was performed in each replication cohort using standard (1.d.f) χ2 
statistic. To assess combined genetic effects, we performed meta-analysis of all studies using 
the inverse-variance method assuming fixed-effect model. We also tested random-effects 
model using DerSimonian-Laird method34 and between-study heterogeneity was assessed 
using the Cochran’s Q and I2 metrics.  Heterogeneity was considered significant if Phet < 0.05. 
The population attributable risk (PAR) for markers showing association with PDB was 
calculated according to the following formula: 
PAR = p(OR-1)/[p(OR-1)+1]; where p is the frequency of the risk allele in controls and OR is 
the risk allele odds ratio. The cumulative PAR was calculated as follows: Cumulative PAR = 
1- (П1→n (1-PARi)); where n is the number of variants and PARi is the individual PAR for the 
ith SNP. The proportion of familial risk attributable to the identified loci was calculated as 
previously described35 assuming a multiplicative model of association and a sibling relative 
risk λs = 7.0 as estimated from previous epidemiological studies22.  Regional association plots 
were generated using the locuszoom tool36. 
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eQTL analysis. SNPs showing genome wide significant association with PDB (or those in 
strong LD; D’≥0.8) were tested for association with cis-allelic expression of gene transcripts 
located in the associated regions using publicly available eQTL data24,37-40. Only cis-acting 
allelic associations located within 250 kb of either 5’ or 3’ end of the associated gene with 
expression P-value < 1 x 10-5 were considered. To avoid false detection, we excluded 
expression data if the gene probe contained a polymorphic SNP or was located in a highly 
repetitive sequence.  
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